BG64095B1 - Дихидрат на епросартан и метод за неговото получаване и използване в лекарствени форми - Google Patents

Дихидрат на епросартан и метод за неговото получаване и използване в лекарствени форми Download PDF

Info

Publication number
BG64095B1
BG64095B1 BG102822A BG10282298A BG64095B1 BG 64095 B1 BG64095 B1 BG 64095B1 BG 102822 A BG102822 A BG 102822A BG 10282298 A BG10282298 A BG 10282298A BG 64095 B1 BG64095 B1 BG 64095B1
Authority
BG
Bulgaria
Prior art keywords
compound
pharmaceutical composition
preparation
acid
dihydrate
Prior art date
Application number
BG102822A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102822A (en
Inventor
Nageswara PALEPU
Gopadi Venkatesh
Sarma Duddu
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG64095(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of BG102822A publication Critical patent/BG102822A/xx
Publication of BG64095B1 publication Critical patent/BG64095B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
BG102822A 1996-03-29 1998-10-07 Дихидрат на епросартан и метод за неговото получаване и използване в лекарствени форми BG64095B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1441496P 1996-03-29 1996-03-29
PCT/US1997/004877 WO1997036874A1 (en) 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation

Publications (2)

Publication Number Publication Date
BG102822A BG102822A (en) 1999-11-30
BG64095B1 true BG64095B1 (bg) 2003-12-31

Family

ID=21765344

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102822A BG64095B1 (bg) 1996-03-29 1998-10-07 Дихидрат на епросартан и метод за неговото получаване и използване в лекарствени форми

Country Status (36)

Country Link
EP (1) EP0889880B1 (ro)
JP (1) JP4316013B2 (ro)
CN (2) CN1214682A (ro)
AP (1) AP901A (ro)
AR (1) AR006439A1 (ro)
AT (1) ATE239723T1 (ro)
AU (1) AU726694B2 (ro)
BG (1) BG64095B1 (ro)
BR (1) BR9708336A (ro)
CA (1) CA2250395C (ro)
CZ (1) CZ293345B6 (ro)
DE (1) DE69721749T2 (ro)
DK (1) DK0889880T3 (ro)
DZ (1) DZ2199A1 (ro)
EA (1) EA001958B1 (ro)
EG (1) EG23889A (ro)
ES (1) ES2198564T3 (ro)
HK (1) HK1016594A1 (ro)
HU (1) HU228263B1 (ro)
ID (1) ID16507A (ro)
IL (1) IL126319A0 (ro)
MA (1) MA24437A1 (ro)
MY (1) MY117682A (ro)
NO (2) NO311760B1 (ro)
NZ (1) NZ332008A (ro)
OA (1) OA11176A (ro)
PL (1) PL188816B1 (ro)
PT (1) PT889880E (ro)
RO (1) RO118870B1 (ro)
SK (1) SK282346B6 (ro)
TR (1) TR199801954T2 (ro)
TW (1) TW434239B (ro)
UA (1) UA49880C2 (ro)
UY (1) UY24504A1 (ro)
WO (1) WO1997036874A1 (ro)
ZA (1) ZA972686B (ro)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262102B1 (en) * 1997-06-27 2001-07-17 Smithkline Beecham Corporation Eprosartan monohydrate
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
AU750611B2 (en) * 1997-11-17 2002-07-25 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
ID25640A (id) 1998-03-04 2000-10-19 Takeda Chemical Industries Ltd Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
WO2000004862A2 (en) * 1998-07-20 2000-02-03 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
GB9820405D0 (en) 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
AU1157500A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
DK1197223T3 (da) * 1999-04-28 2005-05-30 Takeda Pharmaceutical Farmaceutisk præparat til forebyggelse, behandling eller udviklingsinhibition af simpel retinopati eller præproliferativ retinopati
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
CZ20023381A3 (cs) * 2000-04-12 2003-02-12 Novartis Ag Kombinované farmaceutické prostředky obsahující antagonistu AT1-receptoru nebo/a inhibitor HMG-CoA reduktázy nebo/a ACE inhibitor
AU2002364381A1 (en) * 2001-11-23 2003-06-10 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
RU2004137109A (ru) * 2002-05-17 2005-10-10 Новартис АГ (CH) Комбинация блокатора рецептора ангиотензина ii и бетаблокатора для вторичной профилактики инфаркта миокарда
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP3045174A1 (en) 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
WO2009013760A2 (en) 2007-07-25 2009-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101333216A (zh) 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
AU9137791A (en) * 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids

Also Published As

Publication number Publication date
ZA972686B (en) 1997-09-29
HUP9902769A3 (en) 2000-04-28
EP0889880A4 (en) 1999-06-23
AU2547097A (en) 1997-10-22
EP0889880A1 (en) 1999-01-13
EG23889A (en) 2007-12-12
TR199801954T2 (xx) 1998-12-21
DE69721749T2 (de) 2004-03-25
PT889880E (pt) 2003-09-30
HU228263B1 (en) 2013-02-28
NZ332008A (en) 1999-05-28
IL126319A0 (en) 1999-05-09
HK1016594A1 (en) 1999-11-05
HUP9902769A2 (hu) 2000-03-28
EA001958B1 (ru) 2001-10-22
MY117682A (en) 2004-07-31
UA49880C2 (uk) 2002-10-15
CA2250395C (en) 2005-09-06
CZ293345B6 (cs) 2004-04-14
SK282346B6 (sk) 2002-01-07
WO1997036874A1 (en) 1997-10-09
ES2198564T3 (es) 2004-02-01
AR006439A1 (es) 1999-08-25
AU726694B2 (en) 2000-11-16
BR9708336A (pt) 1999-08-03
OA11176A (en) 2003-05-13
JP2000508632A (ja) 2000-07-11
ID16507A (id) 1997-10-02
MA24437A1 (fr) 1998-10-01
EA199800873A1 (ru) 1999-02-25
BG102822A (en) 1999-11-30
DE69721749D1 (de) 2003-06-12
PL329046A1 (en) 1999-03-01
PL188816B1 (pl) 2005-04-29
RO118870B1 (ro) 2003-12-30
CN1332167A (zh) 2002-01-23
TW434239B (en) 2001-05-16
NO984503D0 (no) 1998-09-28
CZ310198A3 (cs) 1999-03-17
DZ2199A1 (fr) 2002-12-03
NO311760B1 (no) 2002-01-21
EP0889880B1 (en) 2003-05-07
DK0889880T3 (da) 2003-09-01
NO984503L (no) 1998-09-28
AP9700956A0 (en) 1997-04-30
NO2002005I1 (no) 2002-09-02
SK132298A3 (en) 1999-03-12
CN1214682A (zh) 1999-04-21
ATE239723T1 (de) 2003-05-15
UY24504A1 (es) 1997-09-19
CA2250395A1 (en) 1997-10-09
JP4316013B2 (ja) 2009-08-19
AP901A (en) 2000-11-23

Similar Documents

Publication Publication Date Title
BG64095B1 (bg) Дихидрат на епросартан и метод за неговото получаване и използване в лекарствени форми
US6558699B2 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US6517871B1 (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
US6630498B2 (en) Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
CA2310028C (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US6420412B2 (en) Eprosartan dihydate and a process for its production and formulation
CA2299470C (en) Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
KR100477295B1 (ko) 에프로사르탄이수화물,그의제조방법및조성물
CZ2001227A3 (cs) Biologicky zlepšené prostředky obsahující eprosartan v orální pevné dávkové formě